New model mimics patents’ response to current chemotherapy regimens
A novel in vitro model has been developed, which mimics the chemoresistance seen in mantle cell lymphoma patients after about 3 years of treatment. This work could help improve clinical outcomes for patients of the most aggressive form of non-Hodgkin’s lymphoma.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>